Ítem
Acceso Abierto

Uso de dexmedetomidina como tratamiento coadyuvante de síndrome de abstinencia alcohólica: revisión sistemática

Mostrar el registro sencillo de la publicación
dc.contributor.advisorAcosta González, Pilar Julieta
dc.contributor.advisorLa Rota Hernández, Jaime Fernando
dc.creatorTolosa Rodríguez, Miguel Antonio
dc.creator.degreeEspecialista en Toxicología Clínica
dc.date.accessioned2016-12-02T16:40:24Z
dc.date.available2016-12-02T16:40:24Z
dc.date.created2016-07-29
dc.date.issued2016
dc.descriptionEl objetivo de este estudio es establecer si la dexmedetomidina (DEX) es segura y efectiva para el manejo coadyuvante de síndrome de abstinencia a alcohol (SAA) a través de la búsqueda de evidencia científica. Metodología: se realiza una revisión sistemática de literatura publicada y no publicada desde enero de 1989 hasta febrero 2016 en PubMed, Embase, Scopus, Bireme, Cochrane library y en otras bases de datos y portales. Los criterios de inclusión fueron ensayos clínicos aleatorizados y no aleatorizados, estudios cuasi-experimentales, estudios de cohorte, y estudios de casos y controles; que incluyeron pacientes mayores de 18 años hospitalizados con diagnóstico de SAA y donde se usó DEX como terapia coadyuvante. Resultados: 7 estudios, 477 pacientes, se incluyeron en el análisis final. Se encontraron dos ensayos clínicos aleatorizados, tres estudios de casos y controles y dos estudios de cohorte retrospectivo. Solo uno de los estudios fue doble ciego y utilizó placebo como comparador. Análisis y conclusiones: en los estudios experimentales se determinan que el uso de DEX como terapia coadyuvante en el manejo de SAA tiene significancia clínica y estadística para disminuir dosis de BZD en las primeras 24 horas de tratamiento; pero no demostraron tener otros beneficios clínicos. En los estudios no aleatorizados existe consenso que relaciona el uso de DEX con menores dosis de BZD de forma temprana. Recomendaciones: no se recomienda el uso de DEX en SAA de forma rutinaria. Se recomienda usar DEX solo en casos en el que exista evidencia fallo terapéutico a BZD.spa
dc.description.abstractSystematic review about dexmedetomidine adjuntive use in the treatment of alcohol withdrawal syndromeeng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_12660
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/12660
dc.language.isospa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentFacultad de Medicinaspa
dc.publisher.programToxicología Clínicaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto completo)spa
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombiaspa
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.source.bibliographicCitationCarlson RW, Kumar NN, Wong-Mckinstry E, Ayyagari S, Puri N, Jackson FK, et al. Alcohol withdrawal syndrome. Crit Care Clin. 2012;28(4):549-85.
dc.source.bibliographicCitationGold J, Nelson L. Ethanol withdrawal. Goldfrank's toxicologic emergencies. 9th ed. New York: McGraw-Hill Medical,; 2011. p. 1134-40.
dc.source.bibliographicCitationFriedmann PD. Clinical practice. Alcohol use in adults. N Engl J Med. 2013;368(4):365-73.
dc.source.bibliographicCitationKattimani S, Bharadwaj B. Clinical management of alcohol withdrawal: A systematic review. Ind Psychiatry J. 2013;22(2):100-8.
dc.source.bibliographicCitationAmato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev. 2011(6).
dc.source.bibliographicCitationNtais C, Pakos E, Kyzas P, Ioannidis JP. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev. 2005(3)
dc.source.bibliographicCitationGuglielminotti J, Maury E, Alzieu M, Delhotal Landes B, Becquemont L, Guidet B, et al. Prolonged sedation requiring mechanical ventilation and continuous flumazenil infusion after routine doses of clorazepam for alcohol withdrawal syndrome. Intensive Care Med. 1999;25(12):1435-6.
dc.source.bibliographicCitationMantz J, Josserand J, Hamada S. Dexmedetomidine: new insights. Eur J Anaesthesiol. 2011;28(1):3-6.
dc.source.bibliographicCitationGregoretti C, Moglia B, Pelosi P, Navalesi P. Clonidine in perioperative medicine and intensive care unit: more than an anti-hypertensive drug. Curr Drug Targets. 2009;10(8):799-814.
dc.source.bibliographicCitationFrazee EN, Personett HA, Leung JG, Nelson S, Dierkhising RA, Bauer PR. Influence of dexmedetomidine therapy on the management of severe alcohol withdrawal syndrome in critically ill patients. J Crit Care. 2014;29(2):298-302.
dc.source.bibliographicCitationMueller SW, Preslaski CR, Kiser TH, Fish DN, Lavelle JC, Malkoski SP, et al. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med. 2014;42(5):1131-9.
dc.source.bibliographicCitationGore FM, Bloem PJ, Patton GC, Ferguson J, Joseph V, Coffey C, et al. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet. 2011;377(9783):2093-102.
dc.source.bibliographicCitationRehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373(9682):2223-33.
dc.source.bibliographicCitationWang YP, Andrade LH. Epidemiology of alcohol and drug use in the elderly. Curr Opin Psychiatry. 2013;26(4):343-8.
dc.source.bibliographicCitationGobierno Nacional de la República de Colombia. Estudio nacional de consumo de sustancias psicoactivas en Colombia - 2013. En; Ministerio de Justicia. Bogotá 2013.
dc.source.bibliographicCitationde Wit M, Jones DG, Sessler CN, Zilberberg MD, Weaver MF. Alcohol-use disorders in the critically ill patient. Chest. 2010;138(4):994-1003.
dc.source.bibliographicCitationRayner SG, Weinert CR, Peng H, Jepsen S, Broccard AF. Dexmedetomidine as adjunct treatment for severe alcohol withdrawal in the ICU. Ann Intensive Care. 2012;2(1):12.
dc.source.bibliographicCitationMuzyk AJ, Kerns S, Brudney S, Gagliardi JP. Dexmedetomidine for the treatment of alcohol withdrawal syndrome: rationale and current status of research. CNS Drugs. 2013;27(11):913-20.
dc.source.bibliographicCitationLlano MC, Campuzano M. La chicha, una bebida fermentada a través de la historia: Instituto Colombiano de Antropología; 1994.
dc.source.bibliographicCitationAssociation AP. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5®): American Psychiatric Publishing; 2013.
dc.source.bibliographicCitationYip L. Ethanol. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum N, editors. Goldfrank's Toxicologic Emergencies. Ninth ed. New York: McGraw Hill; 2011. p. 1115-28.
dc.source.bibliographicCitationCuesta JD, Restrepo AM. Síndrome de abstinencia alcohólica. In: Peña LM, Arroyave CL, Aristizabal JJ, Gómez UE, editors. Toxicología clínica. 1 ed. Colombia: CIB Corporacion para Investigacion Biologica; 2010.
dc.source.bibliographicCitationOlsen RW, Spigelman I. GABAA Receptor Plasticity in Alcohol Withdrawal. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
dc.source.bibliographicCitationReynolds PM, Mueller SW, MacLaren R. A comparison of dexmedetomidine and placebo on the plasma concentrations of NGF, BDNF, GDNF, and epinephrine during severe alcohol withdrawal. Alcohol. 2015;49(1):15-9.
dc.source.bibliographicCitationEyer F, Schuster T, Felgenhauer N, Pfab R, Strubel T, Saugel B, et al. Risk assessment of moderate to severe alcohol withdrawal--predictors for seizures and delirium tremens in the course of withdrawal. Alcohol. 2011;46(4):427-33.
dc.source.bibliographicCitationSullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84(11):1353-7.
dc.source.bibliographicCitationSchmidt KJ, Doshi MR, Holzhausen JM, Natavio A, Cadiz M, Winegardner JE. A Review of the Treatment of Severe Alcohol Withdrawal. Ann Pharmacother. 2016.
dc.source.bibliographicCitationTolonen J, Rossinen J, Alho H, Harjola VP. Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium. Eur J Emerg Med. 2013;20(6):425-7.
dc.source.bibliographicCitationBielka K, Kuchyn I, Glumcher F. Addition of dexmedetomidine to benzodiazepines for patients with alcohol withdrawal syndrome in the intensive care unit: a randomized controlled study. Ann Intensive Care. 2015;5(1).
dc.source.bibliographicCitationAlbertson TE, Chenoweth J, Ford J, Owen K, Sutter ME. Is It Prime Time for Alpha2-Adrenocepter Agonists in the Treatment of Withdrawal Syndromes? J Med Toxicol. 2014;10(4):369-81.
dc.source.bibliographicCitationHoffman BB, Williams FM. Adrenergic Pharmacology. In: Golan DE, Tashjian AH, Armstrong EJ, editors. Principles of pharmacology: the pathophysiologic basis of drug therapy. Third ed: Lippincott Williams & Wilkins; 2011. p. 132-46.
dc.source.bibliographicCitationNikolic K, Agbaba D. Imidazoline antihypertensive drugs: selective i(1) -imidazoline receptors activation. Cardiovasc Ther. 2012;30(4):209-16.
dc.source.bibliographicCitationMuzyk AJ, Fowler JA, Norwood DK, Chilipko A. Role of alpha2-agonists in the treatment of acute alcohol withdrawal. Ann Pharmacother. 2011;45(5):649-57.
dc.source.bibliographicCitationDeMuro JP, Botros DG, Wirkowski E, Hanna AF. Use of dexmedetomidine for the treatment of alcohol withdrawal syndrome in critically ill patients: A retrospective case series. J Anesth. 2012;26(4):601-5.
dc.source.bibliographicCitationPrommer E. Review article: dexmedetomidine: does it have potential in palliative medicine? Am J Hosp Palliat Care. 2011;28(4):276-83.
dc.source.bibliographicCitationEbert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93(2):382-94.
dc.source.bibliographicCitationMohorn PL, Vakkalanka JP, Rushton W, Hardison L, Woloszyn A, Holstege C, et al. Evaluation of dexmedetomidine therapy for sedation in patients with toxicological events at an academic medical center. Clin Toxicology. 2014;52(5):525-30.
dc.source.bibliographicCitationRayner SG, Jepsen S, Peng H, Broccard AF. Dexmedetomidine to treat severe alcohol withdrawal refractory to benzodiazepines. American Journal of Respiratory and Critical Care Medicine. 2011;183(1).
dc.source.bibliographicCitationAbdulmajeed F, Carpenter M, Boutros N. Dexmedetomidine (DEX) as a monotherapy in treating delirium tremens (DTs). Chest. 2013;144(4).
dc.source.bibliographicCitationJackson F, Cooper T, Medina-Garcia L, Williamson T, Shashikumar S, Carlson R. Evolving management of alcohol withdrawal syndrome (AWS): Impact on ICU course and complications. Critical Care Medicine. 2012;40(12):286-7.
dc.source.bibliographicCitationPerry EC. Inpatient management of acute alcohol withdrawal syndrome. CNS Drugs. 2014;28(5):401-10.
dc.source.bibliographicCitationHospira®. Product Information: Precedex(TM) intravenous injection, dexmedetomidine HCl intravenous injection. Lake Forest, IL 60045 USA: Hospira, Inc. (per FDA); 2013.
dc.source.bibliographicCitationRiva JJ, Malik KMP, Burnie SJ, Endicott AR, Busse JW. What is your research question? An introduction to the PICOT format for clinicians. The Journal of the Canadian Chiropractic Association. 2012;56(3):167-71.
dc.source.bibliographicCitationKallio A, Scheinin M, Koulu M, Ponkilainen R, Ruskoaho H, Viinamaki O, et al. Effects of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on hemodynamic control mechanisms. Clin Pharmacol Ther. 1989;46(1):33-42.
dc.source.bibliographicCitationHiggins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
dc.source.bibliographicCitationDabrow Woods A, Giometti R, Weeks SM. The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review. JBI Database System Rev Implement Rep. 2015;13(1):224-52.
dc.source.bibliographicCitationBelka KY. Application of dexmedetomidin for sedation of patients in alcohol withdrawal state in the ICU. Klin Khir. 2015(7):62-4.
dc.source.bibliographicCitationLinn DD, Loeser KC. Dexmedetomidine for Alcohol Withdrawal Syndrome. Annals of Pharmacotherapy. 2015;49(12):1336-42.
dc.source.bibliographicCitationWong A, Smithburger PL, Kane-Gill SL. Review of adjunctive dexmedetomidine in the management of severe acute alcohol withdrawal syndrome. American Journal of Drug and Alcohol Abuse. 2015;41(5):382-91.
dc.source.bibliographicCitationAwissi DK, Lebrun G, Fagnan M, Skrobik Y. Alcohol, nicotine, and iatrogenic withdrawals in the ICU. Critical Care Medicine. 2013;41(9 SUPPL.1):S57-S68.
dc.source.bibliographicCitationSavel RH, Kupfer Y. Using dexmedetomidine as adjunctive therapy for patients with severe alcohol withdrawal syndrome: Another piece of the puzzle. Critical Care Medicine. 2014;42(5):1298-9.
dc.source.bibliographicCitationAbbruscato A, Baron J, Wang S, DeMuro J. Use of dexmedetomidine for treatment of alcohol withdrawal syndrome: Review of the current literature. OA Alcohol. 2014;2(2).
dc.source.bibliographicCitationLucyk S, Hoffman RS, Nelson LS. Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium. Eur J Emerg Med. 21. England2014. p. 389-90.
dc.source.bibliographicCitationSlim J. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Journal of Emergency Medicine. 2014;47(2):254.
dc.source.bibliographicCitationDemuro JP, Wirkowski E, Hanna AF. Response to "benzodiazepine misadventure in acute alcohol withdrawal: The transition from delirium tremens to ICU delirium". Journal of Anesthesia. 2013;27(1):137-8.
dc.source.bibliographicCitationJohnson MT, Yamanaka TT, Fraidenburg DR, Kane SP. Benzodiazepine misadventure in acute alcohol withdrawal: The transition from delirium tremens to ICU delirium. Journal of Anesthesia. 2013;27(1):135-6.
dc.source.bibliographicCitationLizotte RJ, Kappes JA, Bartel BJ, Hayes KM, Lesselyoung VL. Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal. Clin Pharmacol. 2014;6:171-7.
dc.source.bibliographicCitationHodgman T, Teevan C. Use of adjunctive dexmedetomidine for alcohol withdrawal in a large community ICU. Critical Care Medicine. 2013;41(12):A237.
dc.source.bibliographicCitationSmith A, Cwik J, Stone A. Dexmedetomidine as an adjunctive agent in the management of alcohol withdrawal in critically ill. Critical Care Medicine. 2013;41(12):A218-A9.
dc.source.bibliographicCitationAmusina O, Zell-Kanter M, Clouse A, Leikin JB. Dexmedetomidine as an adjunct in patients undergoing treatment for ethanol withdrawal in the critical care setting. Clin Toxicology. 2012;50(7):579-80.
dc.source.bibliographicCitationFoster C, Mueller S, Vanderweide L, Kiser T, Fish D, MacLaren R. Addition of dexmedetomidine to the standard of care for severe alcohol withdrawal. Crit Care Med. 2012;40(12):23.
dc.source.bibliographicCitationGrelle JL, King SE, Haase KK. Dexmedetomidine as adjunctive therapy in alcohol withdrawal syndrome patients in an intensive care unit. Pharmacotherapy. 2012;32(10):e191.
dc.source.bibliographicCitationVijayakumar DG, Kumaran SS, Jena N. Dexmedetomidine as an adjunct in patients undergoing treatment for ethanol withdrawal in the critical care setting. Indian Journal of Crit Care Med. 2014;18:S62.
dc.source.bibliographicCitationMuzyk AJ, Revollo JY, Rivelli SK. The use of dexmedetomidine in alcohol withdrawal. J Neuropsychiatry Clin Neurosci. 24. United States2012. p. E45-6.
dc.source.bibliographicCitationTamada N, Matsuzaki S, Matsuda T, Yamaguchi Y. Use of dexmedetomidine in a critically ill patient with hyperactive delirium: A case report. Masui. 2012;61(10):1108-11.
dc.source.bibliographicCitationDailey RW, Leatherman JW, Sprenkle MD. Dexmedetomidine in the management of alcohol withdrawal and alcohol withdrawal delirium. Am J Respir Crit Care Med. 2011;183(1).
dc.source.bibliographicCitationPeterson LK, Wiegand T. Dexmedetomidine as effective adjunctive agent in the treatment of a patient with severe alcohol and benzodiazepine withdrawal. Clin Toxicology. 2011;49(6):543.
dc.source.bibliographicCitationDarrouj J, Puri N, Prince E, Lomonaco A, Spevetz A, Gerber DR. Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. Ann Pharmacoth. 2008;42(11):1703-5.
dc.source.bibliographicCitationBamgbade OA. Dexmedetomidine for peri-operative sedation and analgesia in alcohol addiction. Anaesthesia. 2006 Mar;61(3):299-300
dc.source.bibliographicCitationRovasalo A, Tohmo H, Aantaa R, Kettunen E, Palojoki R. Dexmedetomidine as an adjuvant in the treatment of alcohol withdrawal delirium: a case report. Gen Hosp Psychiatry. 2006 Jul-Aug;28(4):362-3.
dc.source.bibliographicCitationDuenas C, Serpa A, Caez C, Ortiz-Ruiz G. Dexmedetomidina como tratamiento coadyuvante en pacientes con síndrome de abstinencia por alcohol- delirium tremens. Acta Colomb Cuid Intensivo. 2011;11(2):100-2.
dc.source.bibliographicCitationHarris ZM, Alonso A, Kennedy TP. Adrenergic Inhibition with Dexmedetomidine to Treat Stress Cardiomyopathy during Alcohol Withdrawal: A Case Report and Literature Review. Case Rep Crit Care. 2016;2016:9.
dc.source.bibliographicCitationClark BJ, Moss M, Overdier KH, Keniston A, Burnham EL, Doody M, et al. Dexmedetomidine as an adjunctive therapy for critically ill patients with severe alcohol withdrawal syndrome. Am J Respir Crit Care Med. 2012;185.
dc.source.bibliographicCitationMazanikov M, Udd M, Kylanpaa L, Mustonen H, Lindstrom O, Halttunen J, et al. Dexmedetomidine impairs success of patient-controlled sedation in alcoholics during ERCP: a randomized, double-blind, placebo-controlled study. Surg Endosc. 2013;27(6):2163-8.
dc.source.bibliographicCitationLeong C, Rachwalski E, Lizza B, Cooper C. Retrospective comparison of alpha-2 agonists for alcohol withdrawal in the MICU. Crit Care Med. 2015;43(12):138.
dc.source.bibliographicCitationBrink H, Peitz G, Klepser D, Olsen K. Comparison of dexmedetomidine as adjunct therapy to benzodiazepines vs. Standard benzodiazepine therapy in treatment of alcohol withdrawal syndrome. Crit Care Med. 2012;40(12):259-60.
dc.source.bibliographicCitationAu T, Malesker M, Hilleman D, Walters R, Wichman C, Morrow L. A retrospective analysis of dexmedetomidine use for alcohol withdrawal syndrome in critical care patients. Chest. 2014;146(4).
dc.source.bibliographicCitationKachalia A, Kachalia K, Nagalli S, Lopez R, Rizzo V. Analysis of safety and efficacy of dexmedetomidine as adjunctive therapy for alcohol withdrawal in intensive care unit. Am J Respir Crit Care Med. 2014;189.
dc.source.bibliographicCitationCrispo AL, Daley MJ, Pepin JL, Harford PH, Brown CV. Comparison of clinical outcomes in nonintubated patients with severe alcohol withdrawal syndrome treated with continuous-infusion sedatives: dexmedetomidine versus benzodiazepines. Pharmacotherapy. 2014;34(9):910-7.
dc.source.bibliographicCitationVanderWeide LA, Foster CJ, MacLaren R, Kiser TH, Fish DN, Mueller SW. Evaluation of Early Dexmedetomidine Addition to the Standard of Care for Severe Alcohol Withdrawal in the ICU: A Retrospective Controlled Cohort Study. J Intensive Care Med. 2016;31(3):198-204.
dc.source.bibliographicCitationFerreira JA, Wieruszewski PM, Cunningham DW, Davidson KE, Weisberg SF. Approach to the Complicated Alcohol Withdrawal Patient. J Intensive Care Med. 2015.
dc.source.bibliographicCitationWong A, Benedict NJ, Kane-Gill SL. Multicenter evaluation of pharmacologic management and outcomes associated with severe resistant alcohol withdrawal. Jof Crit Care. 2015;30(2):405-9.
dc.source.bibliographicCitationMirijello A, D'Angelo C, Ferrulli A, Vassallo G, Antonelli M, Caputo F, et al. Identification and management of alcohol withdrawal syndrome. Drugs. 2015;75(4):353-65.
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subjectDexmedetomidinaspa
dc.subjectDesordenes asociados a uso de alcoholspa
dc.subjectSíndrome de abstinencia alcoholspa
dc.subjectBenzodiazepinasspa
dc.subjectCuidado intensivospa
dc.subjectBenzodiacepinasspa
dc.subjectAlcoholspa
dc.subjectAlcoholismospa
dc.subject.ddcEnfermedades
dc.subject.decsDelirio por Abstinencia Alcohólicaspa
dc.subject.decsDexmedetomidinaspa
dc.subject.keywordDexmedetomidineeng
dc.subject.keywordAlcohol Use Disordereng
dc.subject.keywordAlcoholismeng
dc.subject.keywordAlcoholeng
dc.subject.keywordbenzodiazepineseng
dc.subject.keywordIntensive careeng
dc.subject.keywordAlcohol withdrawal syndromeeng
dc.titleUso de dexmedetomidina como tratamiento coadyuvante de síndrome de abstinencia alcohólica: revisión sistemáticaspa
dc.typemasterThesiseng
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTrabajo de gradospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
USO-DE-DEXMEDETOMIDINA-COMO-TRATAMIENTO-COADYUVANTE-DE-SINDROME-DE-ABSTINENCIA-ALCOHOLICA_-REVISION-SISTEMATICA.pdf
Tamaño:
1003.69 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Especialización en Toxicología Clínica